• 1
    Salcman M. Glioblastoma and malignant astrocytomas. In: KayeAH, LawsER. eds. Brain Tumours: an encyclopaedic approach. New York: Churchill Livingstone, 1995. p 44977.
  • 2
    Cavenee WK, Bigner DD, Newcomb EW, Paulus W, Kleihues P. Diffuse astrocytomas. In: KleihuesP, CaveneeWK, eds. Pathology and genetics, tumours of the nervous system, Lyon: IARC Press, 1999. p 210.
  • 3
    Silbergeld DL, Chicoine MR. Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg 1997; 86: 52531.
  • 4
    Goldbrunner RH, Bernstein JJ, Tonn J-C. Cell-extracellular matrix interaction in glioma invasion. Acta Neurochir 1999; 141: 295305.
  • 5
    Knudson CB, Knudson W. Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB J 1993; 7: 123341.
  • 6
    Aspberg A, Miura R, Bourdoulous S, Shimonaka M, Heinegrad D, Schachner M, Ruoslahti E, Yamaguchi Y. The C-type lectin domains of lecticans, a family of aggregating chondroitin sulfate proteoglycans, bind tenascin-R by protein-protein interactions independent of carbohydrate moiety. Proc Natl Acad Sci USA 1997; 94: 1011621.
  • 7
    Seidenbecher CI, Smalla KH, Fischer N, Gundelfinger ED, Kreutz MR. Brevican isoforms associate with neural membranes. J Neurochem 2002; 83: 73846.
  • 8
    Gary SC, Kelly GM, Hockfield S. BEHAB/brevican: a brain-specific lectican implicated in gliomas and glial cell motility. Curr Opin Neurobiol 1998; 8: 57681.
  • 9
    Gary SC, Zerillo CA, Chiang VL, Gaw JU, Gray G, Hockfield S. cDNA cloning, chromosomal localization, and expression analysis of human BEHAB/brevican, a brain specific proteoglycan regulated during cortical development and in glioma. Gene 2000; 256: 13947.
  • 10
    Brakebusch C, Seidenbecher CI, Asztely F, Rauch U, Matthies H, Meyer H, Krug M, Bockers TM, Zhou X, Kreutz MR, Montag D, Gundelfinger ED, et al. Brevican-deficient mice display impaired hippocampal CA1 long-term potentiation but show no obvious deficits in learning and memory. Mol Cell Biol 2002; 22: 741727.
  • 11
    Nutt CL, Matthews RT, Hockfield S. Glial tumour invasion: a role for the upregulation and cleavage of BEHAB/brevican. Neuroscientist 2001; 7: 11322.
  • 12
    Jaworski DM, Kelly GM, Hockfield S. The CNS-specific hyaluronan binding protein, BEHAB, is expressed during periods of glial cell generation and motility. Semin Neurosci 1996; 8: 3916.
  • 13
    Zhang H., Kelly G., Zerillo C., Jaworski D.M, Hockfield S. Expression of a cleaved brain-specific extracellular matrix protein mediates glioma cell invasion in vivo. J Neurosci 1998; 18: 23706.
  • 14
    Tang BL. ADAMTS: a novel family of extracellular matrix proteases. Int J Biochem Cell Biol 2001; 22: 3344.
  • 15
    Tucker RP. The thrombospondin type 1 repeat superfamily. Int J Biochem Cell Biol 2004; 36: 96974.
  • 16
    Tortorella MD, Pratta M, Liu RQ, Austin J, Ross OH, Abbaszade I, Burn T, Arner E. Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4). J Biol Chem 2000; 275: 1856673.
  • 17
    Llamazares M, Cal S, Quesada V, Lopez-Otin C. Identification and characterization of ADAMTS-20 defines a novel subfamily of metalloproteinases-disintegrins with multiple thrombospondin-1 repeats and a unique GON domain. J Biol Chem 2003; 278: 133829.
  • 18
    Hurskainen TL, Hirohata S, Seldi MF, Apte SS. ADAM-TS 5, ADAM-TS 6, and ADAM-TS 7, a novel members of a new family of zinc metalloproteases. General features and genomic distribution of the ADAM-TS family. J Biol Chem 1999; 274: 2555563.
  • 19
    Matthews RT, Gary SC, Zerillo C, Patta M, Solomon K, Arner EC, Hockfield S. BEHAB/brevican cleavage in a glioma cell line is mediated by an ADAMTS family member. J Biol Chem 2000; 275: 22695703.
  • 20
    Feindt J, Becker I, Blömer U, Hugo H-H, Mehdorn HM, Krisch B, Mentlein R. Expression of somatostatin receptor subtypes in cultured astrocytes and gliomas. J Neurochem 1995; 65: 19972005.
  • 21
    Feindt J, Schmidt A, Mentlein R. Receptors and effects of the inhibitory neuropeptide somatostatin in microglial cells. Mol Brain Res 1998; 60: 22833.
  • 22
    Pufe T, Bartscher M, Petersen W, Tillmann B, Mentlein R. Expression of pleiotrophin, an embryonic growth and differentiation factor, in rheumatoid arthritis. Arthritis Rheum 2003; 48: 6607.
  • 23
    Pufe T, Harde V, Petersen W, Goldring MB, Tillmann B, Mentlein R. Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in chondrocytes. J Pathol 2004; 164: 18592.
  • 24
    Held-Feindt J, Mentlein R. CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumours. Int J Cancer 2002; 98: 3526.
  • 25
    Blömer U, Naldini L, Verma IM, Trono D, Gage FH. Applications of gene therapy to the CNS. Hum Mol Genet 1996; 5: 1397404.
  • 26
    Wang P, Tortorella M, England K, Malfait AM, Thomas G, Arner EC, Pei D. Proprotein convertase furin interacts with and cleaves pro-ADAMTS4 (Aggrecanase-1) in the trans-Golgi network. J Biol Chem 2004; 279: 1543440.
  • 27
    Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 36274.
  • 28
    Binder DK, Berger MS. Proteases and the biology of glioma invasion. J Neurooncol 2002; 56: 14958.
  • 29
    Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, Muzik H, Leco KJ, Johnston RN, Brasher PM, Sutherland G, Edwards DR. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 1999; 79: 182835.
  • 30
    Belien AT, Paganetti PA, Schwab ME. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J Cell Biol 1999; 144: 37384.
  • 31
    Kondraganti S, Mohanam S, Chintala SK, Kin Y, Jasti SL, Nirmala C, Lakka SS, Adachi Y, Kyritsis AP, Ali-Osman F, Sawaya R, Fuller GN, et al. Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res 2000; 60: 68515.
  • 32
    Okada Y. Tumour cell-matrix interaction: pericellular matrix degradation and metastasis. Verh Dtsch Ges Pathol 2000; 84: 3342.
  • 33
    Levicar N, Nutall RK, Lah TT. Proteases in brain tumour progression. Acta Neurochir 2003; 145: 82538.
  • 34
    Yamanishi Y, Boyle DL, Clark M, Maki RA, Tortorella MD, Arner EC, Firestein GS. Expression and regulation of aggrecanase in arthritis: the role of TGF-beta. J Immunol 2002; 168: 140512.
  • 35
    Bevitt DJ, Mohamed J, Catterall JB, Li Z, Arris CE, Hiscott P, Sheridan C, Langton KP, Barker MD, Clarke MP, McKie N. Expression of ADAMTS metalloproteinases in the retinal pigment epithelium derived cell line ARPE-19: transcriptional regulation by TNFα. Biochim Biophys Acta 2003; 1626: 831.
  • 36
    Bau B, Gebhard PM, Haag J, Knorr T, Bartnik E, Aigner T. Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum 2002; 46: 264857.
  • 37
    Tortorella MD, Liu RQ, Burn T, Newton RC, Arner E. Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4). Matrix Biol 2002; 21: 499511.
  • 38
    Nakamura H, Fujii Y, Inoki I, Sugimoto K, Tanzawa K, Matsuki H, Miura R, Yamaguchi Y, Okada Y. Brevican is degraded by matrix metalloproteinases and aggrecanase-1 (ADAMTS4) at different sites. J Biol Chem 2000; 275: 3888590.